10% owner Juniper Investment Company sold 242,000 shares of OFIX at $10.70 on 2026-05-22; stock down 45.4% from 52-week high.
Juniper Investment Company, a 10% owner of Orthofix Medical Inc., sold 242,000 shares (242.0K shares) at $10.70, reducing holdings to 3,461,216 shares (3.46M shares). The current price of $9.27 stands 45.4% below the 52-week high and the stock has fallen 19.3% over the past 30 days and 31.5% over 90 days. The company is unprofitable with net income of $-20,908,000.00 ($-20.9M) in the latest quarter, though annual revenue growth is modestly positive at +2.8%. The insider's cross-ticker track record shows 18 prior sells with a 90-day well-timed rate of 31.25%, suggesting mixed execution history across positions. This sale occurs amid significant recent price deterioration and continued unprofitability, warranting examination of whether this represents a shift in the insider's conviction at this holding.
Director John Henneman purchases 5,000 shares at market; stock down from highs amid company's ongoing losses.
John Henneman, a director of Orthofix Medical, purchased 5,000 shares on the open market, increasing his stake by a meaningful portion. The timing is noteworthy: the stock is trading well below its recent highs, having declined over the past quarter, which is a classic setup for insider conviction purchases. However, this conviction is tempered by the company's financial reality — Orthofix is currently unprofitable with negative earnings in both the latest quarter and full-year results, even as revenue shows modest growth. Henneman's purchase history shows he has been a consistent buyer on the open market in recent months, suggesting a sustained conviction despite the company's near-term profitability challenges. This is a director with direct board-level insight putting real money into the company during a period of weakness, which could signal either genuine confidence in a turnaround or simply routine portfolio maintenance by someone with deep knowledge of ongoing strategic efforts.
LP Engine Capital Management acquires ~185k OFIX shares across three days in early May, adding to May 2026 stake.
LP Engine Capital Management, a 10% institutional owner of Orthofix Medical, deployed over $2.2 million to acquire roughly 185,000 shares across three consecutive trading days in early May. Rather than signaling insider conviction about the company's direction, this series of purchases represents a portfolio management decision by an investment fund navigating a challenging stock environment — the shares trade well below their 52-week high and the company remains unprofitable with significant net losses in both the latest quarter and full year. This is the fund's third accumulation of OFIX shares within recent months, but the prior two buys, made in late February, produced losses within both near-term and longer-term horizons, illustrating the fund's mixed track record with this specific stock. The conflicting 30-day versus 90-day outcomes from prior purchases (all five prior trades declined sharply in the month following, though one recovered over a longer period) suggest the fund is averaging down into a volatile holding rather than timing a technical bottom or fundamental inflection. Without evidence of operational improvement or positive catalyst proximity, this appears to be mechanical accumulation by an institutional holder with capital to deploy, not a vote of confidence in an imminent turnaround.
Add OFIX to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.
